Adaptive Biotechnologies Corp. is a leading pharmaceutical company in the United States that specializes in immune-driven medicine. With a low risk ESG score of 18.9, the company is dedicated to transforming disease diagnosis and treatment by leveraging the adaptive immune system. They offer the FDA-authorized clonoSEQ clinical diagnostic product for detecting and monitoring minimal residual disease in patients with various types of cancer. This innovative company is revolutionizing the healthcare industry with its cutting-edge technology and solutions.